Combinations of iOnctura’s roginolisib revert immune suppression in immunotherapy-resistant NSCLC
Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC Data demonstrated roginolisib-containing regimens were tolerable, reduced immunosuppressive activated regulatory T cells (Tregs) and expanded stem-like CD8+ T cells The ‘chemo-free’ (roginolisib plus dostarlimab) arm exhibited the most […]

